FDA says Covid vaccines will probably get an annual update but most people will likely need only one shot

FDA says Covid vaccines will probably get an annual update but most people will likely need only one shot


Justin Sullivan | Getty Images

The Food and Drug Administration has laid out a road map for what Covid-19 vaccination may look like moving forward.

In a briefing document published Monday, the FDA said the vaccines will probably need an annual update as the virus continues to evolve. The agency would select the Covid strain for the vaccine in the spring so the updated shots could roll out every September in time for a fall vaccination campaign.

Most people would receive one shot to restore their protection against the virus moving forward, according to the briefing document. This would apply to people who have been exposed to the virus’s spike protein at least twice, either through vaccination or infection.

But older adults and people with compromised immune systems may need two doses, according to the proposed vaccination schedule. Young children who have received only one shot previously would also get two doses.

The FDA released the road map ahead of a meeting of the agency’s independent vaccine experts scheduled for Thursday. The expert panel will vote on whether to make all Covid vaccines in the U.S. bivalent shots, meaning they protect against both the omicron BA.5 subvariant as well as the original strain of Covid discovered in Wuhan, China, in late 2019.

Currently, only Moderna’s and Pfizer’s booster doses target the omicron variant. If adopted, the primary series would also contain the omicron strain.

The proposed system for updating Covid vaccines resembles how the FDA selects flu shots every year. The agency said it could update and rollout the Covid vaccines without clinical data, which is also the case with the annual process to change the flu shot.

The Centers for Disease Control and Prevention on Thursday is also expected to provide more information about an investigation into what it has described as a “very unlikely” risk of stroke in seniors who received Pfizer’s omicron booster.

The CDC received preliminary safety concern data from its Vaccine Safety Datalink late last year. A subsequent review for four other major databases did not identify an increased risk for stroke, but the CDC investigation is ongoing.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial
Health

Healthy Returns: Eli Lilly’s cholesterol pill impresses in mid-stage trial

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Analysts say […]

Read More
Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits
Health

Dental supply stock rallies on theory RFK’s anti-fluoride stance will prompt more dentist visits

Robert F. Kennedy Jr. attends a campaign event for Republican presidential nominee and former U.S. President Donald Trump in Milwaukee, Wisconsin, U.S. November 1, 2024.  Joel Angel Juarez | Reuters Dental care supplier Henry Schein advanced in Monday trading as investors bet that Robert F. Kennedy Jr., President-elect Donald Trump’s pick for Health and Human […]

Read More
2 health stocks are buys. They’ve been beaten up enough on Trump’s RFK Jr. pick for HHS
Health

2 health stocks are buys. They’ve been beaten up enough on Trump’s RFK Jr. pick for HHS

We are buying 25 shares of Danaher at roughly $229 each. Following Monday’s trade, Jim Cramer’s Charitable Trust will own 550 shares of DHR, increasing its weighting to roughly 3.6% from 3.4%. The health care sector has been the big loser in the market since the election. If the SPDR Health Care Sector Fund , […]

Read More